North Health Ltd. raised $6 million in financing to bring its oncology products to the market including the Neutrocheck, a ...

Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...

Merus NV gained accelerated U.S. FDA approval of Bizengri (zenocutuzumab) as the first and only targeted therapy indicated for NRG1-positive pancreatic adenocarcinoma and non-small-cell lung cancer ...

Our immune cells are not just “defenders” against deadly viruses and pathogens but also a great balancer for tissue ...

A ketone body, a molecule derived from the metabolism of acids to obtain energy when glucose is not available, could become ...

The force is with Field Medical Inc. as it celebrates the U.S. FDA’s decisions to grant breakthrough device designation (BDD) to its Fieldforce ablation system and to accept it into the agency’s Total ...

A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole ...

Although head-to-head results on tolerability were missing from the company’s data release, Eli Lilly and Co. said its U.S. FDA-approved weight-loss drug Zepbound (tirzepatide) beat the also-cleared ...

Eli Lilly and Co.’s weight-loss drug Zepbound (tirzepatide) made headlines yet again as the Indianapolis-based firm disclosed top-line data from the Surmount-5 phase IIIb study. The open-label, ...

Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...

In breast cancer, neoadjuvant chemotherapy reduces the tumor before surgery. However, the response to this treatment does not depend solely on the subtype of malignancies. Other factors could play a ...

Methods that may work well for recruiting and retaining white patients for clinical trials may need to be adjusted to ...